Cue Biopharma reports Phase 2 CSU trial meets primary endpoint for anti-IgE drug CUE-221

Bitget2026/09/21 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cue Biopharma reported positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, supporting a move into Phase 2b/3.
The trial met its primary endpoint, showing clear symptom resolution benefits versus placebo with a generally favorable safety profile.
Efficacy appeared differentiated versus Xolair, with benefits that persisted beyond the dosing period in the highest-dose group.
Complete results, including pharmacokinetic and IgE analyses, will be presented at a future scientific meeting.
Management plans rapid initiation of a Phase 2b/3 registration-enabling study in urticaria, while advancing a separate Phase 2 program in food allergy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-396094), on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cue Biopharma reports Phase 2 CSU trial meets primary endpoint for anti-IgE drug CUE-221

You may also like

Crypto prices